Page 419 - شرور شركات الأدوية

‫ﻣﻼﺣﻈﺎت‬

ws.com/ViewArticle.aspx?d=Policypercent2Bpercent26amppercent3Bpe
rcent2BManagement&d_id=3&i=Marchpercent2B2009&i_id=494&a_id=
12634&ses=ogst.

(2) This story is well covered in Wells F. Fraud and Misconduct in
Biomedical Research. Chapter 5, Fourth ed. RSM Books; 2008. I highly rec-
ommend this book if you want to get started reading about fraud detec-
tion and management. Beware that it’s an academic book, and therefore
appallingly expensive.

(3) Rothwell PM. External validity of randomised controlled trials:
‘To whom do the results of this trial apply?’ The Lancet. 2005 Jan 1;
365(9453):82–93.

(4) Pratt, C.M. & Moye, L.A., 1995. The Cardiac Arrhythmia Suppression
Trial: Casting Suppression in a Different Light. Circulation, 91(1), pp. 245–
247.

(5) Travers, J. et al., 2007. External validity of randomised controlled
trials in asthma: to whom do the results of the trials apply? Thorax, 62(3),
pp. 219–223.

(6) Zimmerman, M., Chelminski, I. & Posternak, M.A., 2004. Exclusion
criteria used in antidepressant efficacy trials: consistency across studies
and representativeness of samples included. The Journal of Nervous and
Mental Disease, 192(2), pp. 87–94.

(7) Keitner, G.I., Posternak, M.A. & Ryan, C.E., 2003. How many subjects
with major depressive disorder meet eligibility requirements of an antide-
pressant efficacy trial? The Journal of Clinical Psychiatry, 64(9), pp. 1091–
3.

(8) Jarvinen TLN, Sievanen H, Kannus P, Jokihaara J, Khan KM. The true
cost of pharmacological disease prevention. BMJ. 2011 Apr 19;342(apr19
1):d2175-d2175.

419